K. Hendren

AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer

Cesar M. Castro, P. Donahoe, M. Birrer, 2015, Proceedings of the National Academy of Sciences.

Abstract A42: An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant c-terminal Mullerian inhibiting substance

P. Donahoe, D. Vavvas, D. Pépin, 2013 .

An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.

A. Marmalidou, F. Nicolaou, L. A. Benedict, 2013, Technology.